Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An infectious process affecting the internal structures of the eye.
Biomarker and diagnostic research for endophthalmitis has been reported in the published literature.
No approved treatments are currently available for endophthalmitis. An additional 2 compounds hold orphan drug designation.
While no drugs are FDA-approved specifically for endophthalmitis, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for endophthalmitis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
8 clinical trials registered, 3 recruiting. Interventions under study include other interventions and drug therapy. Pipeline includes 1 PHASE2, 1 PHASE1, 1 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06624384](https://clinicaltrials.gov/study/NCT06624384) |
Data assembled from 5 of 12 sources · Last updated Sep 17, 2026, 7:49 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Designated
Exclusivity End |
|---|
Designation Status |
|---|
povidone iodine | povidone iodine | Veloce BioPharma LLC | 2017 | — | Designated |
vancomycin | vancomycin | Fera Pharmaceuticals, LLC | 2012 | — | Designated |
Gene therapy approaches for endophthalmitis have been reported in the published literature.
8 trials found
Efficacy and Safety of Topical Cyclosporine 0.05% and Lifitgrast on the Ocular Surface Symptom After Photorefractive Keratectomy in Feiz Hospital, Isfahan, 2024
PHASE1 |
Mohsen Pourazizi |
NOT_YET_RECRUITING |
[NCT07262437](https://clinicaltrials.gov/study/NCT07262437) | Targeting Immunosuppressive Treatment for Non-infectious Uveitis Using Aqueous Humor Cytokine Profiles | NA | University of Milan | ACTIVE_NOT_RECRUITING |
[NCT07175311](https://clinicaltrials.gov/study/NCT07175311) | Vascular Changes Associated With Endophthalmitis. | — | Asociación para Evitar la Ceguera en México | RECRUITING |
[NCT05372861](https://clinicaltrials.gov/study/NCT05372861) | Nanopore Sequencing in Ophthalmology | — | Medical University of Graz | RECRUITING |
[NCT03244072](https://clinicaltrials.gov/study/NCT03244072) | Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery | PHASE2 | Jason Ahee, M.D. | NOT_YET_RECRUITING |
255 publications have been identified in PubMed for endophthalmitis. Kisho has analyzed 136 by research type. Research spans Review / Meta-Analysis (37%), Epidemiology / Natural History (23%), and Case Report / Case Series (21%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 50 | 37% |
Disease patterns and progression | 31 | 23% |
Patient case studies | 28 | 21% |
New treatment approaches | 8 | 6% |
Other research | 5 | 4% |
Testing and diagnosis research | 5 | 4% |
Clinical study results | 5 | 4% |
Laboratory research | 4 | 3% |
Sridhar U (2026). [PMID: 35015464](https://pubmed.ncbi.nlm.nih.gov/35015464/). *Unknown Journal*. [Review / Meta-Analysis]
Zhang C (2026). [PMID: 41666950](https://pubmed.ncbi.nlm.nih.gov/41666950/). *Am J Ophthalmol*. [Case Report / Case Series]
Chen KY (2026). [PMID: 41991784](https://pubmed.ncbi.nlm.nih.gov/41991784/). *Infection*. [Review / Meta-Analysis]
Abakarov SA (2026). [PMID: 42048104](https://pubmed.ncbi.nlm.nih.gov/42048104/). *Vestn Oftalmol*. [Review / Meta-Analysis]
Gurnani B (2026). [PMID: 35015416](https://pubmed.ncbi.nlm.nih.gov/35015416/). *Unknown Journal*. [Review / Meta-Analysis]
Kulkarni A (2026). [PMID: 41714391](https://pubmed.ncbi.nlm.nih.gov/41714391/). *Eye (Lond)*. [Epidemiology / Natural History]
Ly V (2026). [PMID: 32644683](https://pubmed.ncbi.nlm.nih.gov/32644683/). *Unknown Journal*. [Review / Meta-Analysis]
Mochizuki K (2026). [PMID: 42219348](https://pubmed.ncbi.nlm.nih.gov/42219348/). *Med Mycol J*. [Review / Meta-Analysis]
Turner ML (2026). [PMID: 41939082](https://pubmed.ncbi.nlm.nih.gov/41939082/). *Am J Ophthalmol Case Rep*. [Case Report / Case Series]
Markan A (2026). [PMID: 41996231](https://pubmed.ncbi.nlm.nih.gov/41996231/). *Cesk Slov Oftalmol*. [Clinical Trial Publication]